Zenon Konteatis
0000-0002-5421-4907
Publication & Citation Trends
Most Cited Works
Publications
55 total
Reducing hERG Inhibition in the Design of Potent and Bioavailable Indazole cGAS Inhibitors.
Cited by 0
Semantic Scholar
Leveraging Structure-Based Drug Design to Identify Next-Generation MAT2A Inhibitors, Including Brain-Penetrant and Peripherally Efficacious Leads.
Cited by 26
Semantic Scholar
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage
Cited by 225
OpenAlex
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous <i>MTAP</i> Deletion PDF
Cited by 93
OpenAlex
What makes a good fragment in fragment-based drug discovery? OA
Cited by 21
Semantic Scholar
Discovery and Development of Ivosidenib (AG‐120: TIBSOVO ® )
Cited by 1
Semantic Scholar
Molecular mechanisms mediating relapse following ivosidenib monotherapy in IDH1-mutant relapsed or refractory AML PDF
Cited by 192
OpenAlex
Vorasidenib (AG-881): A First-in-Class, Brain-Penetrant Dual Inhibitor of Mutant IDH1 and 2 for Treatment of Glioma PDF
Cited by 181
OpenAlex
Abstract B115: Mitotic defects induced by MAT2A inhibitors guides translational drug combination strategies with AG-270 and taxanes
Cited by 0
Semantic Scholar
Abstract 2714: Targeting MAT2A in CDKN2A/MTAP-deleted cancers
Cited by 1
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(14)
Epigenetics and DNA Methylation
(8)
Computational Drug Discovery Methods
(6)
Receptor Mechanisms and Signaling
(6)
Chronic Myeloid Leukemia Treatments
(6)
Frequent Co-Authors
Affiliations
Seton Hall University
Merck & Co., Inc., Rahway, NJ, USA (United States)
Providence College
Ansys (United States)
Analytical Services